ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2250

Evaluation of Preexisting Renal Disease in Nephrectomies

Session Information

Category: Pathology and Lab Medicine

  • 1602 Pathology and Lab Medicine: Clinical

Authors

  • Salcedo Betancourt, Juan David, University of Miami School of Medicine, Miami, Florida, United States
  • Iakymenko, Oleksii, University of Miami School of Medicine, Miami, Florida, United States
  • Goodrich, Kenny Alexander, University of Miami School of Medicine, Miami, Florida, United States
  • Rozas, Jhoan B., University of Miami School of Medicine, Miami, Florida, United States
  • Philips, Ragi, University of Miami School of Medicine, Miami, Florida, United States
  • Fornoni, Alessia, University of Miami School of Medicine, Miami, Florida, United States
  • Contreras, Gabriel, University of Miami School of Medicine, Miami, Florida, United States
  • Parekh, Dipen, University of Miami School of Medicine, Miami, Florida, United States
  • Barisoni, Laura, Duke University School of Medicine, Durham, North Carolina, United States
  • Florindez, Jorge A., University of Miami School of Medicine, Miami, Florida, United States
  • Thomas, David B., IYM Health Financial Services, PLLC, Charlotte, North Carolina, United States
  • Munoz Mendoza, Jair, University of Miami School of Medicine, Miami, Florida, United States
Background

Evaluation of non-neoplastic renal parenchyma in nephrectomies is part of the College of American Pathologists (CAP) Cancer Protocols. We aimed to determine the prevalence of pre-existing renal diseases in all patients who underwent nephrectomy for any cause in our center.

Methods

The surgical pathology protocol for nephrectomies was modified with a) additional sampling of non-tumoral renal parenchyma, b) Hematoxylin and eosin, Periodic acid-Schiff, trichrome and silver stains, and c) addition of the expanded checklist for reporting nephrectomy from the Renal Pathology Society recommendations. All samples were reviewed by 2 trained nephropathologist (NP). A total of 813 nephrectomies (49% partial and 51% radical) performed between 2013 and 2017 were evaluated and included in the study. Reasons for nephrectomies were malignancy in 645 (79%) of patients, of which 528 (82%) had renal cell carcinoma, 100 (16%) urothelial carcinoma, and 168 (21%) benign lesions (42 oncocytomas, 34 pyelonephritis, 13 trauma, and 8 nephrolithiasis). Clinical, demographic, and pathological data were collected by chart review.

Results

The mean age was 60 ± 14 years. 62% were male and 44% Hispanics, 59% had hypertension, 22% had diabetes mellitus, and 24% had a history of smoking. Baseline eGFR was 73 ± 27 ml/min/1.73m2 and 31% had an eGFR < 60 ml/min/1.73m2. Only 41 patients (5%) had a documented pre-operative consult to nephrology. 296 (36%) patients had at least one renal disease diagnosis and only 62 (8%) had a single diagnosis. 374 pathological diagnoses were reported including focal segmental glomerulosclerosis (FSGS) (157), mostly NOS variant (88%), diabetic glomerulosclerosis (57), interstitial nephritis (66), arterionephrosclerosis (39), pyelonephritis (36), acute tubular injury (10), chronic sclerosing glomerulonephritis (4), amyloidosis (1) and atheroembolic renal disease (1).

Conclusion

Pre-existing renal disease are frequently identified in nephrectomy specimens. FSGS was the most common diagnosis. A collaborative effort involving nephrologists, urologists and pathologists is warranted to improve the care of patients undergoing surgical nephrectomy.